The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer.
William John Gradishar
No relevant relationships to disclose
Thomas Denis Bachelot
Research Funding - Novartis
Stephen Saletan
Employment or Leadership Position - Novartis
Anne Marie Graham
Employment or Leadership Position - Novartis
Pedro Emanuel Rubini Liedke
No relevant relationships to disclose
Sergio Jobim Azevedo
No relevant relationships to disclose
Virote Sriuranpong
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Fatima Cardoso
Consultant or Advisory Role - Novartis
Research Funding - Novartis